SILEREC 25 sildenafil (as citrate) 25 mg film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

silerec 25 sildenafil (as citrate) 25 mg film-coated tablets blister pack

accord healthcare pty ltd - sildenafil citrate, quantity: 35.125 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hypromellose; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 25 mg tablets is not indicated for use by women.

SOLIFENACIN LUPIN solifenacin succinate 10 mg film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

solifenacin lupin solifenacin succinate 10 mg film-coated tablets blister pack

generic health pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; hypromellose; titanium dioxide; purified talc; macrogol 6000; iron oxide red - solifenacin lupin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

SOLIFENACIN LUPIN solifenacin succinate 5 mg film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

solifenacin lupin solifenacin succinate 5 mg film-coated tablets blister pack

generic health pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; hypromellose; titanium dioxide; purified talc; iron oxide yellow; macrogol 6000 - solifenacin lupin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

BUSULFAN ACCORD busulfan 60 mg/10 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

busulfan accord busulfan 60 mg/10 ml concentrated injection vial

accord healthcare pty ltd - busulfan, quantity: 60 mg - injection, concentrated - excipient ingredients: macrogol 400; dimethylacetamide - busulfan accord is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

UPTRAVI 1000 microgram Israel - English - Ministry of Health

uptravi 1000 microgram

j-c health care ltd - selexipag - film coated tablets - selexipag 1000 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

UPTRAVI 1200 microgram Israel - English - Ministry of Health

uptravi 1200 microgram

j-c health care ltd - selexipag - film coated tablets - selexipag 1200 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

UPTRAVI 1400 microgram Israel - English - Ministry of Health

uptravi 1400 microgram

j-c health care ltd - selexipag - film coated tablets - selexipag 1400 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

UPTRAVI 1600 microgram Israel - English - Ministry of Health

uptravi 1600 microgram

j-c health care ltd - selexipag - film coated tablets - selexipag 1600 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

UPTRAVI 200 microgram Israel - English - Ministry of Health

uptravi 200 microgram

j-c health care ltd - selexipag - film coated tablets - selexipag 200 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease

UPTRAVI 400 microgram Israel - English - Ministry of Health

uptravi 400 microgram

j-c health care ltd - selexipag - film coated tablets - selexipag 400 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease